Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch

While early revenue was impacted by a high volume of late-line patients with shorter treatment durations, management expects revenue stability to improve as first-line patient penetration increases through 2026. The company is emphasizing Ibtrozi’s differentiated clinical profile, specifically its 50-month median duration of response in TKI-naive patients and its favorable safety profile. The CEO highlighted the drug’s unique measured inhibition of TRKB, which supports intracranial disease control while avoiding the severe neurological toxicities seen in other therapies.

To expand the drug’s reach, Nuvation Bio has initiated the TRUST-4 Phase 3 study in the adjuvant setting, targeting early-stage patients who require high tolerability for long-term adherence. Beyond Ibtrozi, Nuvation Bio Inc. (NYSE:NUVB) is advancing its second lead program, safusidenib, for IDH1-mutant glioma. The company recently launched the Phase 3 SIGMA trial for high-grade patients, who currently have no approved targeted options, with a projected readout in 2029. Additionally, a smaller Phase 2 cohort for grade 3 oligodendroglioma is underway with results expected by 2027, potentially offering an accelerated approval pathway.

Copyright: epstock / 123RF Stock Photo

Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company that develops therapeutic candidates for oncology. Its lead product candidate is taletrectinib, which is an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.